EVG + Background regimen
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Immune Deficiency Syndrome (AIDS)
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Trial Timeline
Aug 26, 2013 → Nov 3, 2017
NCT ID
NCT01923311About EVG + Background regimen
EVG + Background regimen is a phase 2/3 stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome (AIDS). The current trial status is terminated. This product is registered under clinical trial identifier NCT01923311. Target conditions include Acquired Immune Deficiency Syndrome (AIDS), HIV Infections.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01923311 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Acquired Immune Deficiency Syndrome (AIDS)